The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Negative hyperselection as a predictive biomarker of benefit from first-line doublets + anti-EGFRs/bevacizumab (bev) in microsatellite stable (pMMR/MSS) RAS and BRAF wild-type (wt) and HER2- metastatic colorectal cancer (mCRC): An individual patient data pooled analysis of seven clinical trials (CTs).
 
Marco Maria Germani
Travel, Accommodations, Expenses - Amgen; Merck
 
Roberto Moretto
No Relationships to Disclose
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Guardant Health; Miyarisan pharmaceutical; Myriad Genetics; Takata Pharmaceutical
Consulting or Advisory Role - Guardant Health
 
Volker Heinemann
Stock and Other Ownership Interests - BioNTech SE
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck; MSD; Novartis; Oncosil; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; SERVIER; Sirtex Medical
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; GlaxoSmithKline; IOMX; Isofol Medical; Janssen; Merck; MSD; Natera; Nordic Bioscience; Oncosil; Pierre Fabre; Roche; Servier/Pfizer; SYSMEX; Takeda
Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst); Servier (Inst)
Expert Testimony - Oncosil; Servier
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; MSD; Nordic Bioscience
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Incyte; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Revolution Medicines; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); BeOne (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Johnson & Johnson/Janssen; Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Sebastian Stintzing
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb GmbH; Daiichi Sankyo Europe GmbH; Merck KGaA; MSD; Nordic Bioscience; Pfizer; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; CV6 Therapeutics; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Isofol Medical; Merck KGaA; MSD; Nordic Bioscience; Pierre Fabre; Roche; Seagen; SERVIER; TERUMO
Research Funding - Amgen (Inst); Merck Serono (Inst); MSD (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Servier (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Francesca Bergamo
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Takeda; Teysuno
Speakers' Bureau - AstraZeneca; Bayer; BMS; Lilly; MSD Oncology; Pierre Fabre
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis
 
Kei Muro
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Alan Venook
Consulting or Advisory Role - Abbvie; Amgen; Eisai; Exact Sciences; Exelixis; INTERA; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Lena Weiss
Honoraria - Roche Pharma AG; SERVIER
Consulting or Advisory Role - Merck KGaA; Roche Pharma AG
Research Funding - Illumina
Travel, Accommodations, Expenses - Amgen; Merck KGaA
 
Giulia Martini
Honoraria - Incyte; Pierre Fabre; Servier
 
Francesca Battaglin
No Relationships to Disclose
 
Jumpei Soeda
Employment - Takeda
 
Eva Blondeaux
Speakers' Bureau - Lilly
Research Funding - Gilead Sciences (Inst)
 
Davide Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Sanofi
 
Heinz-Josef Lenz
Honoraria - Abbvie; Adagene; Bayer; Boehringer Ingelheim; Fulgent Genetics; Janssen Oncology; Jazz Pharmaceuticals; Merck Serono; Merus; Roche
Consulting or Advisory Role - 3T BioSciences; Abbvie; Adagene; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Dominik Modest
Honoraria - 21up; Abbvie; Amgen; AstraZeneca; Bicara Therapeutics; Bristol-Myers Squibb; Cor2Ed; GlaxoSmithKline; IKF Klinische Krebsforschung; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; Rottapharm Biotech; Seagen; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AIO gGmbH; Amgen; Cor2Ed; GlaxoSmithKline; IKF Klinische Krebsforschung; Incyte; Jazz Pharmaceuticals; Lilly; Merck Serono; Onkowissen; Onkowissen; Pierre Fabre; Regeneron; SERVIER; Takeda
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Medscape; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Bicara Therapeutics; GlaxoSmithKline; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Research Funding - Amgen; Bayer (Inst); Merck (Inst); Nordic Bioscience; Pierre Fabre; Roche (Inst); SERVIER; Takeda